Opinion: miRNAs – The new wave of molecular cancer therapeutics

Cutting-edge advances in nanomedicine and the recent approval of two siRNA-based therapeutics by the Food and Drug Administration (FDA) has rekindled the interest in RNA interference (RNAi) as vehicles for the development of novel cancer therapeutics. In this perspective, we will briefly discuss how...

Full description

Bibliographic Details
Main Authors: Hernando Lopez-Bertoni, John Laterra
Format: Article
Language:English
Published: Elsevier 2021-06-01
Series:Translational Oncology
Online Access:http://www.sciencedirect.com/science/article/pii/S1936523321000565